New indication for Eisai's Fycompa in Europe

Japanese pharma major Eisai (TYO: 4523) has received approval from the European Commission for the use of its in-house discovered and developed anti-epileptic agent (AED) Fycompa (perampanel) in the treatment of pediatric patients.

This approval extends the use of Fycompa as an adjunctive therapy for partial-onset seizures (POS) (with or without secondary generalization) by expanding the approved age range from 12 years and above to four years and above, and for primary generalized tonic-clonic seizures (PGTCS) from 12 years and above to seven years and above.